… difficile infection (CDI) relies on the antibiotics vancomycin, … difficile, evaluate their potential
as alternative drug targets, … the aim of pointing out possibilities for future treatment strategies. …

… difficile are available, and alternative therapeutic strategies must be implemented. In particular,
new therapeutics … Innovative therapeutic strategies are urgently needed to protect the …

… CDI whose infections did not respond to standard therapies. A report of seven cases
confirmed that six of the seven patients were treated successfully with tigecycline therapy with …

… difficile infection (CDI) is now among the most common causes of hospital-acquired
infection along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant …

… vancomycin remain the front-line therapies for most Clostridium difficile infections (CDI).
However, … difficile and prevent primary and/or recurrent CDI. This therapeutic strategy is currently …

… other therapeutic … infection due to the original infecting organism or infection by a new
strain. Poor antibody responses to C difficile toxins have a permissive role in recurrent infection…

… of infections, more effective therapies against C. difficile are needed but, at the same time,
these therapies … difficile infection, a summary of current therapies and those in developmental …

… As traditional, standard CDI antibiotic therapies (metronidazole and vancomycin) are limited
… rates, novel therapeutic strategies for CDI are needed. Emerging CDI therapies are focused …

… Citation59 Antibodies are poised to become an essential therapeutic strategy in the
management of CDI and bezlotoxumab represents a significant advancement. However, like most …

… difficile is the leading infectious cause of antibiotic‐associated diarrhea and colitis. C. difficile
infection (… infections yearly and an approximate 20% recurrence risk after successful initial …